Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) for Dutasteride Capsules, 0.5 mg. The product is ready for Day 1 launch. The product will be manufactured at the company’s Oral dosage facility at Bangalore and marketed by Strides Shasun in the US Market.
The US market for Dutasteride Capsules is approximately $470 million. The product has gone off patent on November 20, 2015 and Strides Shasun is amongst the first wave of generic players to receive this approval.
Strides Shasun is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Pharmaceutical Services & Active Ingredients.
